| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 25 | 2024 | 972 | 2.260 |
Why?
|
| Cerebral Hemorrhage | 12 | 2024 | 144 | 1.750 |
Why?
|
| Brain Ischemia | 9 | 2022 | 258 | 1.000 |
Why?
|
| Telemedicine | 6 | 2024 | 433 | 0.760 |
Why?
|
| Kentucky | 15 | 2024 | 28 | 0.650 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1015 | 0.600 |
Why?
|
| Ohio | 13 | 2024 | 87 | 0.550 |
Why?
|
| Health Status Disparities | 4 | 2024 | 227 | 0.380 |
Why?
|
| Fibrinolytic Agents | 5 | 2022 | 198 | 0.380 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2022 | 111 | 0.350 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2024 | 74 | 0.340 |
Why?
|
| Stroke Rehabilitation | 2 | 2020 | 59 | 0.330 |
Why?
|
| Hyperglycemia | 2 | 2014 | 222 | 0.330 |
Why?
|
| Aged, 80 and over | 16 | 2024 | 6458 | 0.330 |
Why?
|
| Emergency Medical Services | 4 | 2018 | 436 | 0.320 |
Why?
|
| Sex Factors | 7 | 2020 | 1269 | 0.320 |
Why?
|
| Aged | 27 | 2024 | 19446 | 0.310 |
Why?
|
| Veterans | 5 | 2024 | 1750 | 0.300 |
Why?
|
| Hypertension | 3 | 2024 | 1280 | 0.290 |
Why?
|
| Brain | 2 | 2012 | 3000 | 0.290 |
Why?
|
| Blood Pressure | 3 | 2024 | 1323 | 0.270 |
Why?
|
| Middle Aged | 25 | 2024 | 26440 | 0.260 |
Why?
|
| Mushroom Bodies | 1 | 2005 | 47 | 0.240 |
Why?
|
| Humans | 46 | 2024 | 124399 | 0.230 |
Why?
|
| Intracranial Aneurysm | 2 | 2018 | 93 | 0.230 |
Why?
|
| Apolipoprotein E2 | 2 | 2014 | 13 | 0.220 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 787 | 0.220 |
Why?
|
| Migraine Disorders | 1 | 2024 | 64 | 0.220 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2023 | 9 | 0.210 |
Why?
|
| Male | 31 | 2024 | 60951 | 0.210 |
Why?
|
| Cerebrovascular Disorders | 1 | 2024 | 120 | 0.210 |
Why?
|
| Risk Factors | 12 | 2024 | 10130 | 0.210 |
Why?
|
| Neurology | 1 | 2024 | 108 | 0.200 |
Why?
|
| Opiate Alkaloids | 1 | 2022 | 3 | 0.200 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 210 | 0.200 |
Why?
|
| Emergency Service, Hospital | 6 | 2022 | 1088 | 0.200 |
Why?
|
| Axons | 1 | 2005 | 392 | 0.200 |
Why?
|
| Endocarditis | 1 | 2023 | 106 | 0.190 |
Why?
|
| Incidence | 7 | 2024 | 3082 | 0.190 |
Why?
|
| Female | 29 | 2024 | 66372 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 722 | 0.180 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2024 | 208 | 0.180 |
Why?
|
| Poverty | 1 | 2024 | 419 | 0.180 |
Why?
|
| Cocaine | 1 | 2022 | 206 | 0.180 |
Why?
|
| Recurrence | 1 | 2024 | 1426 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 504 | 0.170 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 511 | 0.170 |
Why?
|
| Drosophila Proteins | 1 | 2005 | 718 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 124 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2014 | 3125 | 0.160 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 154 | 0.160 |
Why?
|
| Thrombolytic Therapy | 3 | 2022 | 204 | 0.160 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 55 | 0.160 |
Why?
|
| Time Factors | 8 | 2024 | 6263 | 0.160 |
Why?
|
| Guideline Adherence | 2 | 2019 | 377 | 0.160 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 1272 | 0.160 |
Why?
|
| Prospective Studies | 8 | 2017 | 6099 | 0.150 |
Why?
|
| Case-Control Studies | 6 | 2016 | 3264 | 0.150 |
Why?
|
| Certification | 1 | 2019 | 67 | 0.150 |
Why?
|
| Deprescriptions | 1 | 2017 | 12 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 458 | 0.140 |
Why?
|
| Cerebral Arteries | 1 | 2018 | 80 | 0.140 |
Why?
|
| Platelet Transfusion | 1 | 2017 | 53 | 0.140 |
Why?
|
| Regional Blood Flow | 1 | 2018 | 209 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 479 | 0.140 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 98 | 0.140 |
Why?
|
| Troponin | 1 | 2017 | 72 | 0.140 |
Why?
|
| Cerebral Angiography | 1 | 2017 | 102 | 0.130 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 429 | 0.130 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2017 | 100 | 0.130 |
Why?
|
| Prevalence | 5 | 2024 | 2428 | 0.130 |
Why?
|
| Retrospective Studies | 11 | 2024 | 16233 | 0.130 |
Why?
|
| Triage | 1 | 2017 | 140 | 0.130 |
Why?
|
| Epilepsy | 1 | 2024 | 868 | 0.130 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2017 | 98 | 0.130 |
Why?
|
| Urban Population | 1 | 2017 | 226 | 0.130 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2015 | 10 | 0.130 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2015 | 10 | 0.130 |
Why?
|
| Cerebral Ventricles | 1 | 2016 | 82 | 0.130 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 70 | 0.120 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 46 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2018 | 371 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 260 | 0.120 |
Why?
|
| Neurons | 1 | 2005 | 1972 | 0.120 |
Why?
|
| Genotype | 4 | 2014 | 2546 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 173 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 635 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1266 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 139 | 0.110 |
Why?
|
| Warfarin | 1 | 2014 | 118 | 0.110 |
Why?
|
| Contrast Media | 1 | 2017 | 479 | 0.110 |
Why?
|
| White Matter | 1 | 2015 | 180 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 1 | 2013 | 73 | 0.100 |
Why?
|
| Apolipoproteins E | 1 | 2013 | 185 | 0.100 |
Why?
|
| SOXF Transcription Factors | 1 | 2012 | 18 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2017 | 477 | 0.100 |
Why?
|
| Anticonvulsants | 1 | 2015 | 377 | 0.100 |
Why?
|
| Sleep | 1 | 2015 | 343 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2017 | 485 | 0.100 |
Why?
|
| Adult | 8 | 2024 | 29422 | 0.100 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 206 | 0.100 |
Why?
|
| Echocardiography | 1 | 2017 | 1051 | 0.090 |
Why?
|
| Treatment Outcome | 9 | 2017 | 12285 | 0.090 |
Why?
|
| United States | 6 | 2024 | 10757 | 0.090 |
Why?
|
| RNA, Long Noncoding | 1 | 2012 | 211 | 0.080 |
Why?
|
| Peptides | 1 | 2013 | 793 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 626 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2014 | 1653 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 2533 | 0.080 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2024 | 668 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1416 | 0.080 |
Why?
|
| Phenotype | 1 | 2018 | 4252 | 0.070 |
Why?
|
| Age Factors | 3 | 2020 | 2811 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1241 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2021 | 539 | 0.070 |
Why?
|
| Reperfusion Injury | 1 | 2006 | 103 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2023 | 4730 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 1886 | 0.060 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2005 | 92 | 0.060 |
Why?
|
| Headache Disorders | 1 | 2024 | 4 | 0.060 |
Why?
|
| Larva | 1 | 2005 | 248 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2005 | 115 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 459 | 0.060 |
Why?
|
| Animals, Genetically Modified | 1 | 2005 | 315 | 0.060 |
Why?
|
| Neurologists | 1 | 2024 | 17 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 392 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2005 | 211 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 5107 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2005 | 403 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 276 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2017 | 1247 | 0.050 |
Why?
|
| Social Class | 1 | 2024 | 190 | 0.050 |
Why?
|
| Educational Status | 1 | 2024 | 270 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 2894 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1802 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2024 | 223 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 239 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 164 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 274 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 18 | 0.050 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 33 | 0.050 |
Why?
|
| Emotions | 1 | 2024 | 365 | 0.050 |
Why?
|
| Occupational Health | 1 | 2021 | 44 | 0.050 |
Why?
|
| Animals | 4 | 2018 | 34128 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 147 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1001 | 0.040 |
Why?
|
| Models, Biological | 1 | 2005 | 1460 | 0.040 |
Why?
|
| Rats | 2 | 2018 | 3687 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2005 | 766 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 449 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 1394 | 0.040 |
Why?
|
| Curriculum | 1 | 2024 | 723 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 396 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 408 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 495 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 296 | 0.040 |
Why?
|
| Rats, Inbred BN | 1 | 2018 | 16 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 225 | 0.040 |
Why?
|
| Basilar Artery | 1 | 2018 | 24 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2021 | 368 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 1411 | 0.040 |
Why?
|
| Ligation | 1 | 2018 | 135 | 0.040 |
Why?
|
| Rats, Long-Evans | 1 | 2018 | 102 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 494 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2018 | 203 | 0.040 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2017 | 10 | 0.040 |
Why?
|
| Ventriculostomy | 1 | 2017 | 36 | 0.040 |
Why?
|
| Halogenation | 1 | 2017 | 5 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2018 | 231 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 583 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 143 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 399 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 518 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 4344 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 586 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2019 | 389 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 229 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 188 | 0.030 |
Why?
|
| Rats, Inbred WKY | 1 | 2015 | 53 | 0.030 |
Why?
|
| Rats, Inbred SHR | 1 | 2015 | 64 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 412 | 0.030 |
Why?
|
| Young Adult | 2 | 2022 | 8972 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 226 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 605 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2005 | 2607 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 582 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2006 | 4532 | 0.030 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2013 | 8 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1479 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1318 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 284 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 749 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 2038 | 0.020 |
Why?
|
| Mutation | 1 | 2005 | 5806 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2823 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 723 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 722 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1156 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1617 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2086 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 3415 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4551 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 1037 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2604 | 0.010 |
Why?
|
| Child | 1 | 2022 | 24486 | 0.010 |
Why?
|